The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
DKN-01 and tislelizumab ± chemotherapy as a first-line (1L) and second-line (2L) investigational therapy in advanced gastroesophageal adenocarcinoma (GEA): DisTinGuish Trial.
 
Samuel J Klempner
Stock and Other Ownership Interests - TP Therapeutics
Honoraria - Natera
Consulting or Advisory Role - Astellas Pharma; Boston Biomedical; Bristol-Myers Squibb; Daiichi Sankyo/UCB Japan; Foundation Medicine; Lilly; Merck; Pieris Pharmaceuticals
Speakers' Bureau - Foundation Medicine
Research Funding - BeiGene (Inst); Leap Therapeutics (Inst)
Other Relationship - NCCN
 
Joseph Chao
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Coherus Biosciences; Daiichi Sankyo; Foundation Medicine; Geneos; Lilly; Macrogenics; Merck; Novartis; Ono Pharmaceutical; Roche; Silverback Therapeutics; Turning Point Therapeutics
Speakers' Bureau - Bristol Myers Squibb; Merck
Research Funding - Brooklyn Immunotherapeutics (Inst); Merck (Inst); Novonco Therapeutics (Inst)
Travel, Accommodations, Expenses - Amgen; Foundation Medicine; Macrogenics; Merck
Other Relationship - Yiviva
 
Hope Elizabeth Uronis
Employment - GeneCentric (I)
Stock and Other Ownership Interests - GeneCentric (I)
Consulting or Advisory Role - AstraZeneca
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Leap Therapeutics; Macrogenics (Inst); Merck (Inst)
 
Cynthia A. Sirard
Employment - Leap Therapeutics
Leadership - Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics
Patents, Royalties, Other Intellectual Property - Pending patent application;Application No. 62/260,959
Travel, Accommodations, Expenses - Leap Therapeutics
 
Michael Kagey
Employment - Biogen (I); Leap Therapeutics
Stock and Other Ownership Interests - Leap Therapeutics; Syros Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I have patents pending and granted for discovery based work at Leap Therapeutics (current employer), Tensha Therapeutics (acquired by Roche) and the Whitehead Institute (licensed to Syros Pharmaceuticals)
 
Jason Baum
Employment - Intercept Pharmaceuticals (I); Leap Therapeutics; Novartis
Stock and Other Ownership Interests - Intercept Pharmaceuticals (I); Leap Therapeutics; Novartis
 
James Song
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
Jin Wang
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene
 
In-Ho Kim
No Relationships to Disclose
 
Keun Wook Lee
Honoraria - Boryung; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; ISU ABXIS
Research Funding - ABL Bio (Inst); ALX Oncology (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BeiGene (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Five Prime Therapeutics (Inst); GC Pharma (Inst); InventisBio (Inst); Leap Therapeutics (Inst); LSK BioPharma (Inst); Macrogenics (Inst); MedPacto (Inst); Merck KGaA (Inst); MSD (Inst); Oncologie (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Trishula Therapeutics (Inst); Y-BIOLOGICS (Inst); Zymeworks (Inst)
 
Do-Youn Oh
Consulting or Advisory Role - ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; Merck Serono; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Bassam Bassam Sonbol
No Relationships to Disclose
 
Zev A. Wainberg
Consulting or Advisory Role - Amgen; Array BioPharma; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Five Prime Therapeutics; Ipsen; Lilly; Macrogenics; Merck; Merck KGaA; Novartis; QED Therapeutics
Research Funding - Five Prime Therapeutics (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst)
Travel, Accommodations, Expenses - Bayer; Lilly; Merck
 
Jaffer A. Ajani
Honoraria - Acrotech Biopharma; Aduro Biotech; Amgen; Astellas Pharma; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Daiichi Sankyo; DAVA Pharmaceuticals; Fresenius Kabi; Gilead Sciences; GRAIL; Lilly; Merck; Novartis; oncotherics; SERVIER; zymeworks
Consulting or Advisory Role - American Cancer Society; BeiGene; Bristol-Myers Squibb; Insys Therapeutics; Merck; Vaccinogen
Research Funding - Amgen; Astellas Pharma (Inst); Bristol-Myers Squibb; Daiichi Sankyo; Delta-Fly Pharma; Gilead Sciences; Lilly/ImClone; Merck; Novartis; ProLynx; Roche/Genentech; Taiho Pharmaceutical; Takeda; Zymeworks
Patents, Royalties, Other Intellectual Property - I have research funding from: Genentech, Roche, BMS, Taiho, MedImmune, Merck, Amgen, Lilly